Serendo Therapeutics is pioneering precision therapies for autoimmune diseases by targeting endophilin A2 (EA2), a novel intracellular modulator of T- and B-cell activation. Current treatments often rely on broad immunosuppression, which can lead to an increased risk of infection and inadequate disease control. EA2 therefore represents a breakthrough opportunity for more targeted, effective and safer interventions.

This pilot project aims to identify and validate small-molecule EA2 inhibitors through high-throughput screening (HTS), in collaboration with the DK-OPENSCREEN platform at DTU. We will transfer and adapt a functional assay to HTS format and perform a pilot screening of small molecule inhibitors. This feasibility study will establish EA2’s druggability and generate a foundation for long-term collaborative research and development. Our vision is to unlock a new class of precision immunotherapies with the potential to transform the care of autoimmune patients with significant unmet medical needs.

For further information about this HALRIC pilot project, please contact:

 

Ulrika Norin
Serendo Therapeutics
ulrika.norin@serendotx.com